ReviewInternational journal of nanomedicine2026
Nanobiosensors for Rheumatoid Arthritis Biomarkers: Advances and Clinical Translational Potential.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article summarizes the development of nanobiological sensors in detecting markers such as serological antibodies related to rheumatoid arthritis(RA) and compares the performance of sensing platforms. In the laboratory, sensing platforms constructed with materials like gold nanoparticles have achieved detection sensitivities from femtomolar to picomolar levels, and some studies have initially verified their availability in samples. In the field of clinical transformation, electrochemical nanobiological sensors are expected to achieve point-of-care testing for RA soon, and optical detection can be used as a high-end platform in central laboratories in the medium term. However, most sensors are at the preclinical verification stage and face many significant challenges. Clinical transformation needs to address overall issues, such as sample pretreatment. This article also explores possible future trends to help provide technical and theoretical support for early diagnosis and treatment of RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.